Ownwell, which uses machine learning and local property tax expertise to help property owners fight hikes in tax assessments, is growing in Houston. Photo via Getty Images

A $5.75 million round of seed funding raised by an Austin-based proptech startup will help the company grow its presence in Houston.

Ownwell’s technology analyzes millions of properties to identify property owners who are overpaying, and the company then offers to protest tax assessments on the owners’ behalf for a 25 percent cut of any savings they realize. The company estimates that nearly nine out of 10 protests are successful, and customers save an average of $1,457.

Ownwell currently employs five people in Houston and expects that number to reach 10 by the end of this year. Overall, 14 of the company’s 29 employees live in the Houston, Austin, Dallas, San Antonio, and Waco areas.

First Round Capital led the $5.75 million round. Additional investors include Wonder Ventures, Founder Collective, Long Journey Ventures, and former PayPal board member Scott Banister. So far, Ownwell has raised $7.5 million in funding.

With the fresh round of funding, Ownwell plans to accelerate hiring in areas such as sales, marketing, technology, and operations.

Ownwell couples machine learning with local property tax expertise to help property owners fight hikes in tax assessments.

“Property owners have a lot to consider when deciding to protest: the costs in time and money, the complexity of the process, and the access to real estate expertise and advice,” Colton Pace, Ownwell’s CEO, says in a news release. “As part of our mission to reduce the inequities of property ownership, Ownwell handles the entire process of appealing on behalf of property owners and charges the lowest fees currently on the market.”

Joseph Noor, Ownwell’s chief technology officer, says each property tax appeal the company files isn’t considered complete “until it has been verified, analyzed, augmented, and finalized by a member of our property tax specialist team.” Ownwell doesn’t earn money unless an appeal succeeds.

“At Ownwell, we strive to provide our clients the benefits of modern technology with the thoughtful touch that can only be imparted by an expert in the field,” Noor tells InnovationMap.

Colton Pace is the CEO of Austin-based Ownwell. Image courtesy of Ownwell

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.